Roy Gandolfi, MD
Internal Medicine · West Valley City, UTNPI 1740211101
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Gen-probe, Inc. at 49.5% of the total. Reporting peaked in 2024 at $4,259 and has fallen 91.2% since, to $375 in 2025. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $44.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gen-probe, Inc.$6K
- Medtronic$834
- Hologic Sales And Service, LLC$612
- Boehringer Ingelheim$573
- Gen-probe Sales & Service, Inc.$533
- Amgen$441
- plus $3K from 36 others
What the payments were for
- Speaking & faculty fees$5,75047%
- Travel & lodging$1,99616%
- Food & beverage$4,49137%
- Education$210%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aptima$3,577
- Minimed 670G System$580
- BTX$577
- EXPAREL$131
How this compares
$12,277 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 242 | $207,783 |
| JardianceEmpagliflozin | 143 | $151,917 |
| OzempicSemaglutide | 73 | $98,101 |
| XareltoRivaroxaban | 66 | $60,768 |
| MounjaroTirzepatide | 57 | $58,439 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $37,887 |
| TrulicityDulaglutide | 18 | $19,687 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,730 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $16,251 |
| FarxigaDapagliflozin Propanediol | 17 | $13,559 |
| Gabapentin | 322 | $10,914 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,253 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $9,615 |
| Omeprazole | 504 | $9,241 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $9,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $327 | $207,783242 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $573 | $162,171165 claims |
| Novo NordiskOzempic | $231 | $98,10173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $148 | $78,12575 claims |
| Johnson & JohnsonXarelto | $233 | $60,76866 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $293 | $22,44936 claims |
| AstraZenecaFarxiga | $197 | $13,55917 claims |
| AbbVieLinzess, Synthroid | $89 | $10,23856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in West Valley City
- Kenneth SchaecherWest Valley City$333K
- Gloria GonzalesWest Valley City$4K
- Kathryn CasullWest Valley City$4K
- Willard DereSalt Lake City$4.7M
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
- Barbara RizzardiSandy$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.